Gene therapy for diabetic peripheral neuropathy: A randomized, placebo‐controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor

• Published in: Clinical and translational science Vol. 14; no. 3; pp. 1176 - 1184
• Main Authors: Kessler, John A., Shaibani, Aziz, Sang, Christine N., Christiansen, Mark, Kudrow, David, Vinik, Aaron, Shin, Nari
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01-05-2021; John Wiley and Sons Inc; Wiley
• Subjects: Adverse events; Aged; Clinical trials; Demographics; Deoxyribonucleic acid; Diabetes; Diabetes mellitus; Diabetic Neuropathies - complications; Diabetic Neuropathies - genetics; Diabetic Neuropathies - therapy; Diabetic neuropathy; DNA; Double-Blind Method; Female; Gabapentin; Gene therapy; Gene transfer; Genetic Therapy - methods; Hepatocyte growth factor; Hepatocyte Growth Factor - genetics; Humans; Injections, Intramuscular; Isoforms; Male; Middle Aged; Muscles; Neuralgia - diagnosis; Neuralgia - genetics; Neuralgia - therapy; Pain; Pain Measurement - statistics & numerical data; Peripheral neuropathy; Placebos; Placebos - administration & dosage; Placebos - adverse effects; Plasmids - administration & dosage; Plasmids - adverse effects; Plasmids - genetics; Protein expression; Proteins; Quality of life; Safety; Treatment Outcome
• ISSN: 1752-8054; 1752-8062
• DOI: 10.1111/cts.12977

VM202 is a plasmid DNA encoding two isoforms of hepatocyte growth factor (HGF). A previous phase II study in subjects with painful diabetic peripheral neuropathy (DPN) showed significant reductions in pain. A phase III study was conducted to evaluate the safety and efficacy of VM202 in DPN. The trial was conducted in two parts, one for 9 months (DPN 3‐1) with 500 subjects (VM202: 336 subjects; and placebo: 164) and a preplanned subset of 101 subjects (VM202: 65 subjects; and placebo: 36) with a noninterventional extension to 12 months (DPN 3‐1b). VM202 or placebo was administered to calf muscles on days 0 and 14, and on days 90 and 104. The primary end point in DPN 3‐1 was change from baseline in the mean 24‐h Numerical Rating Scale (NRS) pain score. In DPN 3‐1b, the primary end point was safety, whereas the secondary efficacy end point was change in the mean pain score. VM202 was well‐tolerated in both studies without significant adverse events. VM202 failed to meet its efficacy end points in DPN 3‐1. In DPN 3‐1b, however, VM202 showed significant and clinically meaningful pain reduction versus placebo. Pain reduction in DPN 3‐1b was even greater in subjects not receiving gabapentin or pregabalin, confirming an observation noted in the phase II study. In DPN 3‐1b, symptomatic relief was maintained for 8 months after the last injection suggesting that VM202 treatment might change disease progression. Despite the perplexing discrepancy between the two studies, the safety and long‐lasting pain‐relieving effects of VM202 observed in DPN 3‐1b warrant another rigorous phase III study.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Current therapies for painful diabetic peripheral neuropathy (DPN) are palliative and do not target the underlying mechanisms. Moreover, symptomatic relief is often limited with existing neuropathic pain drugs. Thus, there is a great medical need for safer and effective treatments for DPN.
WHAT QUESTION DID THIS STUDY ADDRESS?
Can nonviral gene delivery of hepatocyte growth factor reduce pain in patients with DPN and potentially modify progression of the disorder?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
Nonviral gene therapy can be used safely and practically to treat DPN.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
As the first gene medicine to enter advanced clinical trials for the treatment of DPN, this study provides the proof of concept of an entirely new potential approach to the disorder.